Interactions between betaine, insulin resistance, and cognitive impairment in people with and without HIV
Clinical Scorecard: The Relationship of Betaine, Insulin Resistance, and Cognitive Decline in Individuals With and Without HIV
At a Glance
| Category | Detail |
|---|
| Condition | Cognitive decline in individuals with and without HIV |
| Key Mechanisms | Insulin resistance, inflammatory pathways, and metabolic markers |
| Target Population | Individuals with HIV and individuals without HIV |
| Care Setting | Clinical research on metabolic and cognitive health |
Key Highlights
- Higher Diabetes Risk Index (DRI) levels associated with worse cognitive performance.
- Betaine linked to better cognitive performance in people with HIV.
- Insulin resistance may have a greater impact on cognitive health in people with HIV than in those without.
Guideline-Based Recommendations
Diagnosis
- Use neuropsychological testing to assess cognitive performance.
- Evaluate metabolic markers such as GlycA, DRI, and LP-IR.
Management
- Consider dietary and lifestyle interventions to improve metabolic health.
- Monitor betaine levels as a potential therapeutic target.
Monitoring & Follow-up
- Regular assessment of insulin resistance and inflammatory markers.
- Track cognitive performance over time in individuals with HIV.
Risks
- Increased risk of cognitive decline associated with higher insulin resistance.
- Potential for metabolic dysfunction to exacerbate cognitive impairment in individuals with HIV.
Patient & Prescribing Data
Individuals with HIV and diabetes mellitus, and those without HIV.
Betaine may have protective effects against cognitive decline.
Clinical Best Practices
- Incorporate metabolic assessments in cognitive health evaluations for individuals with HIV.
- Address insulin resistance through lifestyle modifications and dietary changes.
Related Resources & Content
